Immune drug anifrolumab linked to lower risk of infection and hospitalization for skin lupus

Preliminary results from an investigator-initiated, single-site objective survey amusement that immoderate radical with chronic cutaneous lupus erythematosus—a benignant of lupus that tin origin imperishable tegument harm and hairsbreadth loss—are little apt to get life-threatening infections erstwhile taking the cause anifrolumab, an FDA-approved monoclonal antibody attraction for systemic lupus erythematosus.